Docstoc

MolMed S.p.A. - Product Pipeline Review - Q4 2010

Document Sample
MolMed S.p.A. - Product Pipeline Review - Q4 2010 Powered By Docstoc
					Brochure
More information from http://www.researchandmarkets.com/reports/1446197/




MolMed S.p.A. - Product Pipeline Review - Q4 2010

Description:    MolMed S.p.A. – Product Pipeline Review – Q4 2010

                Summary

                Global Market Direct’s pharmaceuticals report, “MolMed S.p.A. - Product Pipeline Review - Q4 2010”
                provides data on the company’s research and development focus. The report includes information
                on current developmental pipeline, complete with latest updates, and features on discontinued and
                dormant projects.

                This report is built using data and information sourced from Global Markets Direct’s proprietary
                databases, Company’s corporate website, SEC filings, investor presentations and featured press
                releases, both from company and industry-specific third party sources, put together by Global
                Markets Direct’s team.

                Scope

                - MolMed S.p.A. - Brief company overview including business description, key information and
                facts, and its locations and subsidiaries.
                - Review of current pipeline of MolMed S.p.A. human therapeutic division.
                - Overview of pipeline therapeutics across various therapy areas.
                - Coverage of current pipeline molecules in various stages of drug development, including the
                combination treatment modalities, across the globe.
                - Product profiles for late stage and clinical stage products of MolMed S.p.A. with complete
                description of the product’s developmental history, mechanism of action, therapeutic class, target
                and major milestones.
                - Recent updates of the MolMed S.p.A.’s pipeline in the last quarter.
                - Key discontinued and dormant projects.
                - Latest news and deals relating to the products.

                Reasons to buy

                - Evaluate MolMed S.p.A.’s strategic position with total access to detailed information on its product
                pipeline.
                - Assess the growth potential of MolMed S.p.A. in its therapy areas of focus.
                - Identify new drug targets and therapeutic classes in the MolMed S.p.A.’s R&D portfolio and
                develop key strategic initiatives to reinforce pipeline in those areas.
                - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
                - Exploit collaboration and partnership opportunities with MolMed S.p.A..
                - Avoid Intellectual Property Rights related issues.
                - Explore the dormant and discontinued projects of MolMed S.p.A. and identify potential
                opportunities in those areas.



Contents:
                List of Tables
                List of Figures
                MolMed S.p.A. Snapshot
                MolMed S.p.A. Overview
                Key Information
                Key Facts
                MolMed S.p.A. – Research and Development Overview
                Key Therapeutic Areas
                MolMed S.p.A. – Pipeline Review
                Pipeline Products by Stage of Development
                Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
MolMed S.p.A. – Pipeline Products Glance
MolMed S.p.A. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
MolMed S.p.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
MolMed S.p.A. – Drug Profiles
NGR-hTNF
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF + Vinorelbine
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
TK Cells
Product Description
Mechanism of Action
R&D Progress
M3TK
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF + Doxorubicin
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF + Cisplatin_
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF + Oxaliplatin + Capecitabine
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF + Doxorubicin
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF + Cisplatin_
Product Description
Mechanism of Action
R&D Progress
MolMed S.p.A. – Pipeline Analysis
MolMed S.p.A. – Pipeline Products by Therapeutic Class
MolMed S.p.A. Pipeline Products By Target
MolMed S.p.A. – Pipeline Products by Molecule Type
MolMed S.p.A. – Recent Pipeline Updates
MolMed S.p.A. - Dormant Projects
MolMed S.p.A. – Locations And Subsidiaries
            Head Office
            Recent Developments
            Apr 21, 2010: Results Of Phase II Trial Of NGR-hTNF In Mesothelioma Published By The Journal Of
            Clinical Oncology
            Apr 21, 2010: Results Of Phase II Trial Of NGR-hTNF In Mesothelioma Published By The Journal Of
            Clinical Oncology
            Apr 21, 2010: Results Of Phase II Trial Of NGR-hTNF In Mesothelioma Published By The Journal Of
            Clinical Oncology
            Apr 20, 2010: MolMed Starts Phase III Trial Of NGR-hTNF In Mesothelioma
            Apr 20, 2010: MolMed Starts Phase III Trial Of NGR-hTNF In Mesothelioma
            Apr 20, 2010: MolMed Starts Phase III Trial Of NGR-hTNF In Mesothelioma
            Nov 11, 2009: The European Commission Grants Orphan Drug Designation For MolMed S.p.A.'s
            NGR-hTNF In the Treatment Of Hepatocellular Carcinoma
            Oct 22, 2009: Molmed Wins The Patent Litigation Related To TK Therapy
            Sep 24, 2009: Update Of Clinical Trials Of NGR-hTNF, MolMed’s Anticancer Investigational Biologic
            Drug
            Sep 24, 2009: Update Of Clinical Trials Of NGR-hTNF, MolMed’s Anticancer Investigational Biologic
            Drug
            Financial Deals Landscape
            MolMed S.p.A., Deals Summary, 2004 to 2010
            MolMed S.p.A. Detailed Deal Summary
            Takara Bio Enters Into Collaboration Agreement With MolMed
            Licensing Agreements
            Oxford BioMedica Enters Into Licensing Agreement With MolMed
            Appendix
            Methodology
            Coverage
            Secondary Research
            Primary Research
            Expert Panel Validation
            Contact Us
            Disclaimer



Ordering:   Order Online - http://www.researchandmarkets.com/reports/1446197/

            Order by Fax - using the form below

            Order by Post - print the order form below and sent to

                         Research and Markets,
                         Guinness Centre,
                         Taylors Lane,
                         Dublin 8,
                         Ireland.
                                                           Page 1 of 2

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-
1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.


               Product Name:           MolMed S.p.A. - Product Pipeline Review - Q4 2010
               Web Address:            http://www.researchandmarkets.com/reports/1446197/
               Office Code:            OC8HQQSSMMNVT

Product Formats
Please select the product formats and quantity you require:


                                   Quantity
               Electronic -
                                         EURO €392.00
               Single User:
               Electronic - Site
                                         EURO €784.00
               License:
               Electronic -
                                         EURO €1,177.00
               Enterprisewide:




Contact Information
Please enter all the information below in BLOCK CAPITALS


      Title:                  Mr              Mrs           Dr           Miss                 Ms     Prof

      First Name:                                                  Last Name:

      Email Address: *

      Job Title:

      Organisation:

      Address:

      City:

      Postal / Zip Code:

      Country:

      Phone Number:

      Fax Number:

     * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
                                                              Page 2 of 2

Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

          Pay by credit card:                     American Express

                                                  Diners Club

                                                  Master Card

                                                  Visa
                                           Cardholder's Name

                                           Cardholder's Signature

                                           Expiry Date

                                           Card Number

                                           CVV Number

                                           Issue Date
                                           (for Diners Club only)




          Pay by check:                    Please post the check, accompanied by this form, to:

                                           Research and Markets,
                                           Guinness Center,
                                           Taylors Lane,
                                           Dublin 8,
                                           Ireland.


                                           Please transfer funds to:
          Pay by wire transfer:
                                           Account number                   833 130 83
                                           Sort code                        98-53-30
                                           Swift code                       ULSBIE2D
                                           IBAN number                      IE78ULSB98533083313083
                                           Bank Address                 Ulster Bank,
                                                                        27-35 Main Street,
                                                                        Blackrock,
                                                                        Co. Dublin,
                                                                        Ireland.


     If you have a Marketing Code please enter it below:


           Marketing Code:


      Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
     http://www.researchandmarkets.com/info/terms.asp



                                              Please fax this form to:
                                  (646) 607-1907 or (646) 964-6609 - From USA
                          +353 1 481 1716 or +353 1 653 1571 - From Rest of World

				
DOCUMENT INFO
Categories:
Tags:
Stats:
views:3
posted:1/10/2012
language:
pages:5